The Cystic Fibrosis Foundation's (CFF) $150m investment in therapies developed by Vertex Pharmaceuticals, including Kalydeco (ivacaftor), paid off in a big way: the nonprofit patient advocacy group sold its future royalties from the cystic fibrosis (CF) medicines to Royalty Pharma for $3.3bn.
CFF still is deciding exactly how it will spend the cash and over how long a period, but CF patients...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

